Shares of I-Mab (IMAB) is currently trading at $79.17, up $7.47 or 10.43%, with trading volume of 208K versus an average volume of 587K shares. The stock has been trading between $32.64 and $85.40 for the past one year.
This clinical stage biopharmaceutical company I-Mab, on September 2, 2021, said it has been added to FTSE Global Equity Index Series, following FTSE's most recent semi-annual review. These inclusions will become effective after the market close on Friday, September 17, 2021.
Last month, I-Mab announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome or CRS in patients with severe COVID-19.
For comments and feedback: editorial@rttnews.com